Upgrades Neutral Buy X

DXCM Dexcom

Redburn Atlantic

$85 $115

Upgrades Neutral Outperform X

DXCM Dexcom

Robert W. Baird

$86 $104

Downgrades Overweight Neutral X

DXCM Dexcom

JP Morgan

$145 $75

Downgrades Outperform Neutral X

DXCM Dexcom

Robert W. Baird

$161 $80

Initiated Neutral X

DXCM Dexcom

Redburn Atlantic

$130

Initiated Outperform X

DXCM Dexcom

RBC Capital Mkts

$165

Resumed Equal-Weight X

DXCM Dexcom

Morgan Stanley

$131

Upgrades Outperform Strong Buy X

DXCM Dexcom

Raymond James

$127 $138

Initiated Buy X

DXCM Dexcom

UBS

$142

Initiated Outperform X

DXCM Dexcom

Wolfe Research

$121

Initiated Equal Weight X

DXCM Dexcom

Barclays

$103

Initiated Buy X

DXCM Dexcom

Jefferies

$125

Initiated Outperform X

DXCM Dexcom

Bernstein

$105

Upgrades Neutral Buy X

DXCM Dexcom

BTIG Research

$535

Upgrades Eq Weight Overweight X

DXCM Dexcom

Wells Fargo

$575

Upgrades Neutral Buy X

DXCM Dexcom

Guggenheim

$580

Downgrades Buy Neutral X

DXCM Dexcom

Guggenheim

Resumed Outperform X

DXCM Dexcom

Cowen

$540 $525

Upgrades Underweight Eq Weight X

DXCM Dexcom

Wells Fargo

$380

Initiated Overweight X

DXCM Dexcom

Barclays

$500

Initiated Overweight X

DXCM Dexcom

Atlantic Equities

$438

Upgrades Neutral Buy X

DXCM Dexcom

UBS

$410 $445

Initiated Neutral X

DXCM Dexcom

UBS

$135

Upgrades Sell Neutral X

DXCM Dexcom

Goldman

Upgrades Under Perform Mkt Perform X

DXCM Dexcom

Northland Capital

Reiterated Buy X

DXCM Dexcom

Canaccord Genuity

$105 $125

Upgrades Mkt Perform Outperform X

DXCM Dexcom

Raymond James

Upgrades Neutral Overweight X

DXCM Dexcom

JP Morgan

Initiated Buy X

DXCM Dexcom

BofA/Merrill

$100

Reiterated Buy X

DXCM Dexcom

Canaccord Genuity

$81 $85

Initiated Sell X

DXCM Dexcom

Goldman

$57

Initiated Neutral X

DXCM Dexcom

Guggenheim

DXCM  DexCom, Inc.

Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company's markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient's receiver and an application on the patient's iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).